Dravet syndrome (DS), a catastrophic childhood epilepsy, is associated with severe intellectual disability, impaired social development, persistent drug-resistant seizures and a high risk of sudden unexpected death in epilepsy. We recently began to explore the possibility that single-gene mutations in zebrafish can be used to advance our understanding of the pathophysiology and treatment of DS. Zebrafish mutants featuring a loss-of- function sodium channel (SCN1A) mutation (e.g., a gene family commonly identified in children with DS) were identified and characterized by our laboratory as epileptic zebrafish with phenotypes similar to the human condition. Using automated behavioral tracking and in vivo electrophysiology assays we screened more than 1300 compounds using these fish. With the data generated, we now propose to extend this research program to include novel DS zebrafish mutants, additional high-throughput screening, and mechanistic analysis of a small molecule lead compound that emerged from the first screening effort.
Three specific aims are proposed: (i) to generate and characterize zebrafish DS mutants, (ii) to perform high-throughput drug screening using zebrafish DS mutants, and (iii) to examine the mechanism of action for clemizole in DS mutants. Techniques will include automated locomotion tracking, in vivo zebrafish electrophysiology recording, pharmacology, CRISPR/Cas9 genome editing and calcium imaging using genetically encoded calcium indicators. Our results promise to advance our long-term goal to better understand the pathophysiology of genetic epilepsies, and identify promising new treatment options for these intractable conditions.

Public Health Relevance

With nearly 40,000 children suffering from Dravet Syndrome in desperate need of more effective therapies, and families moving to Colorado based almost on a blind hope for a new treatment, our proposal is squarely focused on a timely and significant unmet need in the pediatric epilepsy community. Combining multiple levels of analysis across several zebrafish models of DS, this proposal aims to provide new insights and treatment for this condition.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS096976-01
Application #
9126735
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Whittemore, Vicky R
Project Start
2016-04-01
Project End
2020-03-31
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
1
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Neurosurgery
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Griffin, Aliesha; Hamling, Kyla R; Knupp, Kelly et al. (2017) Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome. Brain 140:669-683
Grone, Brian P; Qu, Tiange; Baraban, Scott C (2017) Behavioral Comorbidities and Drug Treatments in a Zebrafish scn1lab Model of Dravet Syndrome. eNeuro 4:
Protas, Meredith E; Weh, Eric; Footz, Tim et al. (2017) Mutations of conserved non-coding elements of PITX2 in patients with ocular dysgenesis and developmental glaucoma. Hum Mol Genet 26:3630-3638
Hong, SoonGweon; Lee, Philip; Baraban, Scott C et al. (2016) A Novel Long-term, Multi-Channel and Non-invasive Electrophysiology Platform for Zebrafish. Sci Rep 6:28248
Kumar, Maneesh G; Rowley, Shane; Fulton, Ruth et al. (2016) Altered Glycolysis and Mitochondrial Respiration in a Zebrafish Model of Dravet Syndrome. eNeuro 3:
Grone, Brian P; Marchese, Maria; Hamling, Kyla R et al. (2016) Epilepsy, Behavioral Abnormalities, and Physiological Comorbidities in Syntaxin-Binding Protein 1 (STXBP1) Mutant Zebrafish. PLoS One 11:e0151148
Dinday, Matthew T; Baraban, Scott C (2015) Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet Syndrome eNeuro 2: